Eventide Asset Management

Funding rounds backed by Eventide Asset Management.

Export CSV
Funding disclosed in full
$380M
Median round
$190M
Rounds in calculation
2
2 rounds
LatestLargest
Funding rounds with company descriptions, amounts, stages and announcement dates
CompanyRoundMarketInvestorsAnnouncedDetails
AdvanCell

Develops lead-212 targeted alpha therapies to treat cancer

$315MSeries DBiotechAustralia
19 participantsAbingworthAlly Bridge GroupAlpha WaveBain Capital Life SciencesBrandon CapitalCatalio Capital ManagementEli Lilly and CompanyEventide Asset ManagementFidelity Management & Research CompanyMorningsidePiper HeartlandProto AxiomSanofi VenturesSV Health InvestorsSymBiosisTenmileTime BioVenturesT. Rowe Price AssociatesVelosity Capital
Leo Cancer Care

Designs cancer care systems around the body's natural upright position

$65MSeries DHealthtechUnited States
2 participantsEventide Asset ManagementYu Galaxy